Daiichi initiates pivotal trials for cancer drug nimotuzumab

04/26/2013 | Pharmaceutical Business Review Online

Daiichi Sankyo has started patient enrollment for two late-stage trials of nimotuzumab, its experimental drug for lung and gastric cancer. Nimotuzumab is a recombinant humanized monoclonal antibody that targets the epidermal growth factor receptor. The lung cancer trial will be carried out in Japan while the gastric cancer study will be conducted in Japan and South Korea.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL